References
Adolph EF. Quantitation relations in the physiological constitutions of mammals. Science 109: 579–585, 1949
Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. In Meister (Ed.) Advances in enzymology, Vol. 41, pp. 99–128, Wiley & Sons, New York, 1974
Banks WA, Kastin AJ, Barrera CM. Delivering peptides to the central nervous system: dilemmas and strategies. Pharmaceutical Research 8: 1345–1350, 1991
Baumann G, Amburn KD, Buchanan TA. The effect of circulating growth hormone-binding protein on metabolic clearance, distribution and degradation of human growth hormone. Journal of Clinical Endocrinology and Metabolism 64: 657–660, 1987
Bocci V. Immunomodulators as local hormones: new insights regarding their clinical utilization. Journal of Biological Response Modifiers 4: 340–352, 1985
Bose S, Hickman J. Role of the carbohydrate moiety in determining the survival of interferon in the circulation. Journal of Biological Chemistry 252: 8336–8337, 1977
Boxenbaum H, D’Souza RW. Interspecies pharmacokinetic scaling, biological design, and neoteny. In Testa et al. (Eds) Advances in drug research, Vol. 19, pp. 139–196, Academic Press Limited, London, 1990
Carone FA, Peterson DR, Flouret G. Renal tubular processing of small peptide hormones. Journal of Laboratory and Clinical Medicine 100: 1–14, 1982
Ceska JR, Berglund A, Lundkirst V, Grossmuller F. Influence of the degree of iodination and storage time on the immunological activity of 125I-IgE. Immunochemistry 9: 565–575, 1972
Chappell WR, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. In Testa et al. (Eds) Advances in drug research, Vol. 20, pp. 1–116, Academic Press Limited, London, 1991
Chen AB, Baker DL, Ferraiolo BL. Points to consider in correlating bioassays and immunoassays in the quantitation of peptides and proteins. In Garzone et al. (Eds) Peptides, peptoids and proteins, Vol. 3, pp. 53–71, Harvey Whitney Books, Cincinnati, 1991
Daggett V. Protein degradation: the role of mixed-function oxidases. Pharmaceutical Research 4: 278–284, 1987
Edwards NA. Scaling of renal functions in mammals. Comparative Biochemistry and Physiology 52A: 63–66, 1975
Ferraiolo BL, Fuller GB, Burnett B, Chan E. Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous and subcutaneous administration. Journal of Biological Response Modifiers 7: 115–122, 1988
Ferraiolo BL, Winslow J, Laramee G, Celniker A, Johnston P. Pharmacokinetics and metabolism of human relaxins in rhesus monkeys. Pharmaceutical Research 8: 1032–1038, 1991
Ferraiolo BL, Monier MA. Goals and analytical methodologies for protein disposition studies. In Ferraiolo et al. (Eds) Protein pharmacokinetics and metabolism, Plenum, New York, in press, 1992
Firestone GL, Winguth SD. Immunoprecipitation of proteins. Methods of Enzymology 182: 688–699, 1990
Frohman LA, Downs TR, Williams TC, Heimer EP, Pan Y-CE, et al. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. Journal of Clinical Investigation 78: 906–913, 1986
Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73: 84–89, 1989
Ghezzi P, Saccardo B, Bianchi M. Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochemistry Biophysics Research Communication 136: 316–321, 1986a
Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, et al. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infectious Immunology 54: 837–840, 1986b
Gosling JP. A decade of development of immunoassay methodology. Clinical Chemistry 36: 1408–1427, 1990
Harris R, Frade LG, Creighton LJ, Gascione PS, Alexandroni MM, et al. Investigation by HPLC of the catabolism of recombinant tissue plasminogen activator in the rat. Thrombosis and Haemotology 60: 107–112, 1988
Havredaki M, Barona F. Variations in interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Japanese Journal of Medical Science and Biology 38: 107–111, 1985
Hindmarsh PC, Matthews DR, Brain CE, Pringle PJ, Di Silvio L, et al. The half-life of exogenous growth hormone after suppression of endogenous growth hormone secretion with somatostatin. Clinical Endocrinology 30: 443–450, 1989
Hulse JA, Rosenthal SM, Cuttler L, Kaplan SL, Grumbach MM. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men. Journal of Clinical Endocrinology and Metabolism 63: 872–878, 1986
Jonkman JHG, Nicholson KH, Farrow PR, Eckert M, Grasmeijer G, et al. Effects of alfa-interferon on theophylline pharmacokinetics and metabolism. British Journal of Clinical Pharmacology 27: 795–802, 1989
Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, et al. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Research 45: 2866–2872, 1985
LaBella FS, Geiger JD, Glavin GB. Administered peptides inhibit the degradation of endogenous peptides: the dilemma of distinguishing direct from indirect effects. Peptides 6: 645–660, 1985
LaRusso NF. Proteins in bile: how they get there and what they do. American Journal of Physiology 247: G199–G205, 1984
Lelchuk R, Playfair JHL. Serum IL-2 inhibitor in mice I: increase during infection. Immunology 56: 113–118, 1985
Lochs H, Williams PE, Morse EL, Abumrad NN, Adibi SA. Metabolism of dipeptides and their constituent amino acids by liver, gut, kidney, and muscle. American Journal of Physiology 254: E588–E594, 1988
Maack T, Johnson V, Kau ST, Figueiredo J, Sigulem D. Renal filtration, transport and metabolism of low-molecular-weight proteins: a review. Kidney International 16: 251–270, 1979
MacNamara EM, Whicher JT. Electrophoresis and densitometry of serum and urine in the investigation and significance of monoclonal immunoglobulins. Electrophoresis 11: 376–381, 1990
Matsas R, Kenny AJ, Turner AJ. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11. Biochemical Journal 223: 433–440, 1984
Matsuyama H, Ruhmann-Wennhold A, Johnson LR, Nelson DH. Disappearance rates of exogenous and endogenous ACTH from rat plasma measured by bioassay and radioimmunoassay. Metabolism 21: 30–35, 1972
McMartin C. Pharmacokinetics of peptides and proteins; opportunities and challenges. Advanced Drug Research 22: 39–106, 1992
Mohler MA, Cook J, Baumann G. Binding proteins of protein therapeutics. In Ferraiolo et al. (Eds) Protein pharmacokinetics and metabolism, Plenum, New York, in press, 1992
Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharmaceutical Research 8: 1351–1359, 1991
Nadeau RW, Oldfield NF, Garland WA, Liberato DJ. Quatification of recombinant interleukin-2 in human serum by a specific immunobioassay. Analytical Chemistry 61: 1732–1736, 1989
Nadeau RW, Satoh H, Scheide S, Crowl R, Conroy R, et al. A comparison of mass balance, pharmacokinetics and disposition of 125I and 14C recombinant human interleukin-2 (rhIl-2) in cynomolgus monkeys. Drug Metabolism and Disposition, in press, 1992
Nokta M, Loh JP, Douidar SM, Ahmed AE, Pollard RB. Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients. Journal of Interferon Research 11: 159–164, 1991
Parkinson A, Lasker J, Kramer MJ, Huang M-T, Thomas PE, et al. Effects of three recombinant human leukocyte interferons on drug metabolism in mice. Drug Metabolism and Disposition 10: 579–585, 1982
Philips TM. Isolation and recovery of biologically active proteins by high performance immunoaffinity chromatography. In Kerlavage (Ed.) The use of HPLC in receptor biochemistry, pp. 129–154, Alan R. Liss, New York, 1989
Quiron R. Bioassays in modern peptide research. Peptides 3: 223–230, 1982
Regoeczi E (Ed.) Iodine-labelled plasma proteins, Vol. 2 Part A, pp. 6, 112, 116–117, CRC Press, Boca Raton, 1987a
Regoeczi E (Ed.) Iodine-labelled plasma proteins, Vol. 2 Part B, pp. 43–62, CRC Press, Boca Raton, 1987b
Rochiccioli PE, Tauber MT, Coude FX, Arone M, Morre M, et al. Results of 1-year growth hormone (GH)-releasing hormone-(1-44) treatment on growth, somatomedin-C, and 24h GH secretion in six children with partial GH deficiency. Journal of Clinical Endocrinology and Metabolism 65: 268–274, 1987
Rosa C, Amr S, Birken S, Wehmann R, Nisula B. Effect of desialylation of human chorionic gonadotropin on its metabolic clearance rate in humans. Journal of Clinical Endocrinology and Metabolism 59: 1215–1219, 1984
Ross RJM, Rodda C, Tsagarakis S, Davies PSW, Grossman A, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet 1: 5–8, 1987
Stahl WR. Scaling of respiratory variables in mammals. Journal of Applied Physiology 22: 453–460, 1967
Sugiyama Y, Hanano M. Receptor-mediated transport of peptide hormones and its importance in the overall disposition in the body. Pharmaceutical Research 6: 192–202, 1989
Taylor G, Marafino BJ, Moore JA, Gurley V, Blaschke JF. Interferon reduces hepatic drug metabolism in vivo in mice. Drug Metabolism and Disposition 13: 459–463, 1985
Timmons TM, Dunbar BS. Protein blotting and immunodetection. Methods in Enzymology 182: 679–688, 1990
Vance ML, Kaiser DL, Evans WS, Furlanetto R, Vale W, et al. Pulsatile growth hormone secretion in normal men during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Journal of Clinical Investigation 75: 1584–1590, 1985
Von Wussow P, Borden EC. Antibodies to interferons in patients: defining their significance. Journal of Interferon Research 9 (Suppl. 1): 51–572, 1989
Waldhausl WK, Bratusch-Marrain PR, Vierhapper H, Nowotny P. Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man. Metabolism 32: 478–486, 1983
Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. British Journal of Clinical Pharmacology 22: 610–612, 1986
Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 2: 939–941, 1987
Wills RJ, Dennis SA, Spiegel HE, Gibson DM, Nadler PI. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clinical Pharmacology and Therapeutics 35: 722–727, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wills, R.J., Ferraiolo, B.L. The Role of Pharmacokinetics in the Development of Biotechnologically Derived Agents. Clin. Pharmacokinet. 23, 406–414 (1992). https://doi.org/10.2165/00003088-199223060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199223060-00002